TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1948264
Drug: Proguanil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil (200 mg/day) combined with sulfamethoxazole (1500 mg/day)
Study: 25778685
Drug: Alfacalcidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (0.5 μg/day)
Study: 21161329
Drug: Preemptive warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive warfarin dose reduction (10-20%)
Study: 19524987
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block and intraprostatic local anesthesia with 5 ml 2% lidocaine
Study: 19524987
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block with 0.9% NaCl by intraprostatic injection
Study: 8851903
Drug: Diuretic (D)
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (D)
Study: 1792613
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (2-3 drugs)
Study: 6349944
Drug: Broad-spectrum sunscreen
Normalized name: Titanium Dioxide 0.08 g in 1 g TOPICAL LOTION [ZO MEDICAL OCLIPSE-C Broad-Spectrum Sunscreen SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum sunscreen agent
Study: 30712444
Drug: One-session cognitive
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session cognitive behavior treatment (CBT)
Study: 27197690
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g intravenous on days 1 and 15, and after 26 weeks if needed)
Study: 27197690
Drug: TNF inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitor (adalimumab 40 mg subcutaneously every other week or etanercept 50 mg per week subcutaneously)
Study: 17369792
Drug: Twice per
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice per week leg press exercise (n=11)
Study: 23136
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg orally
Study: 23136
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg orally
Study: 23136
Drug: Practolol 200
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 200 mg orally
Study: 23136
Drug: Pindolol 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 0.05 mg/kg intravenously
Study: 26358523
Drug: Trastuzumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab with chemotherapy
Study: 23596888
Drug: Safflower peony
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower peony ointment single dosage scheme (2.16 g, 4 people; 4.32 g, 6 people; 6.48 g, 6 people; 8.62 g, 6 people; 11.46 g, 6 people; 15.24 g, 6 people) for 24 hours, once every day.
Study: 23596888
Drug: Safflower peony
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower peony ointment multi-dosage scheme (8.62 g, 6 people; 11.46 g, 6 people) once every day for 7 days.
Study: 21539525
Drug: Low Drug
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Drug Burden Index (DBI <1)
Study: 21539525
Drug: High Drug
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Drug Burden Index (DBI ≥1)
Study: 21539525
Drug: Low Drug
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Drug Burden Index (DBI <1) after adjustment
Study: 12162857
Drug: Intravenous doxepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doxepin
Study: 12162857
Drug: Oral doxepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxepin
Study: 2349954
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine supplementation, 100 mg/kg/day for 2 months
Study: 2349954
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral L-carnitine supplementation)
Study: 159841
Drug: Ro 11‐1430
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 11‐1430 (0.1% vanishing cream)
Study: 159841
Drug: Placebo (vanishing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vanishing cream alone)
Study: 25594845
Drug: Barrier-improving cream
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barrier-improving cream (5% urea)
Study: 25594845
Drug: Reference cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference cream
Study: 24076337
Drug: 25% albumin
Normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% albumin (2 g/kg; maximum dose 750 mL)
Study: 17038253
Drug: Glutamine +
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine + TPN (0.27 g.kg(‐1).d(‐1) for 7 days)
Study: 153716
Drug: No EMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No EMG treatment (control group)
Study: 31416011
Drug: SSS07 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSS07 (5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg)
Study: 31416011
Drug: SSS07 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSS07 (5 mg to 100 mg)
Study: 18574608
Drug: Polytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytherapy with two atypical antipsychotics
Study: 18574608
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with atypical antipsychotics
Study: 11966543
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (acid decreasing therapy with H2-receptor antagonist or PPI)
Study: 11966543
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (one antibiotic plus acid-decreasing therapy)
Study: 11966543
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PPI plus amoxicillin and clarithromycin)
Study: 9709461
Drug: Immediate AZT
Normalized name: AZT
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate AZT monotherapy
Study: 9709461
Drug: Deferred AZT
Normalized name: AZT
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred AZT monotherapy
Study: 8620950
Drug: Low-dose salbutamol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose salbutamol metered-dose inhaler (50 micrograms.puff-1)
Study: 8620950
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose salbutamol metered-dose inhaler (100 micrograms.puff-1)
Study: 25226426
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day)
Study: 11130216
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 mg once/day for the first week, 20 mg once/day for the second week, and 40 mg once/day for the remaining 3 weeks
Study: 9050976
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg moxonidine once a day (increased to 0.4 mg after 2 weeks)
Study: 9050976
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg enalapril once a day (increased to 10 mg after 2 weeks)
Study: 2243429
Drug: Colestipol-niacin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol-niacin therapy
Study: 29948418
Drug: TachoSil® patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil® patches
Study: 22574800
Drug: Behaviour Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour Therapy (BT)
Study: 22086903
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (n = 17), 100 minutes of conventional physical therapy daily.
Study: 20592268
Drug: Fugl-Meyer score
Normalized name: meyer lemon extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fugl-Meyer score and treatment intensity
Study: 16043733
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (INH) before meals
Study: 8615554
Drug: Caffeine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (two doses) with paracetamol
Study: 4076324
Drug: Paracetamol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol alone
Study: 1679658
Drug: Terfenadine (H1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (H1-selective histamine antagonist)
Study: 1679658
Drug: Compound 48/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 48/80 (histamine depleting agent)
Study: 7006883
Drug: Timolol 10
Normalized name: timolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 10 to 30 mg twice daily
Study: 25705872
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks nicotine patch treatment
Study: 25705872
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks nicotine patch treatment
Study: 26284723
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (8 weeks)
Study: 22945761
Drug: Bazedoxifene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (20 or 40 mg)
Study: 18201586
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron supplementation (1 g IV iron sucrose administered as a 100 mg dose at each of 10 consecutive HD sessions)
Study: 15288482
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2a 3MIU thrice weekly with ribavirin 800-1,000 mg/day
Study: 15288482
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2a 3MIU daily plus amantadine 200 mg/day with ribavirin 800-1,000 mg/day
Study: 11713358
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for purulent sputum (5 or 10 days)
Study: 11713358
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled steroid (fluticasone) for mucoid sputum (14 days)
Study: 23506344
Drug: Human fibroblast-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human fibroblast-derived dermal substitute (HFDS) plus four-layer compression therapy
Study: 15114104
Drug: Histidine-tryptophan-ketoglutarate (HTK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histidine-tryptophan-ketoglutarate (HTK) solution
Study: 11575413
Drug: Lorazepam followed
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam followed by midazolam (fentanyl 10-15 microg kg(‐1) and midazolam 0.05-0.075 mg kg(‐1) intraoperatively and a midazolam infusion for 3 h postoperatively)
Study: 7527161
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (verapamil, nifedipine, verapamil+nifedipine)
Study: 9494064
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg (steady state)
Study: 9494064
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (steady state)
Study: 9494064
Drug: Biological in
Normalized name: COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological in vitro experiments with pantoprazole
Study: 30554193
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement of 4,000 IU daily for 3 years
Study: 16595246
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day triptorelin administration
Study: 16595246
Drug: Daily triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily triptorelin administration
Study: 16424845
Drug: Insulin-enriched warm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-enriched warm blood cardioplegia (IWBC) (10 UI/L)
Study: 8528638
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative radiation therapy or chemotherapy (control group)
Study: 6775300
Drug: Nitroglycerin microcapsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin microcapsule preparation 2.5 mg
Study: 27693759
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with pediatrician's recommendation to visit parks and written resources (park prescription)
Study: 17342879
Drug: Low dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dairy meal (80 mg Ca+2)
Study: 1595918
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1, 2, or 4 micrograms/kg)
Study: 1595918
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (epidural)
Study: 10352397
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle injection)
Study: 8748889
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (1 tablet daily)
Study: 8748889
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (4 tablets daily)
Study: 8748889
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (2 tablets daily)
Study: 6163573
Drug: Terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5 mg, two tablets)
Study: 1524161
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg daily
Study: 12559533
Drug: Ticlopidine 2
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 2 x 250 mg daily
Study: 11850161
Drug: Piperacillin/tazobactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (2 g/0.5 g/q8h)
Study: 11850161
Drug: Imipenem/cilastatin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (0.5 g/0.5 g/q8h)
Study: 21048536
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (n=54)
Study: 21048536
Drug: Steroid-free immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppression
Study: 21048536
Drug: Steroid bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid bolus therapy
Study: 17932357
Drug: Ibuprofen use
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen use (yes)
Study: 16320746
Drug: Drug (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (group C)
Study: 16320746
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus drug (group E)
Study: 11922399
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 21 days
Study: 8311269
Drug: Fentanyl 5
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 5 micrograms/kg combined with thiopental 3 mg/kg, maintained with isoflurane and fentanyl 0.02 microgram.kg‐1.min‐1
Study: 8311269
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg/kg combined with thiopental 3 mg/kg, maintained with isoflurane and ketamine 20 micrograms.kg‐1.min‐1
Study: 8311269
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg, maintained with isoflurane only
Study: 5303551
Drug: Unbuffered aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unbuffered aspirin ingestion with alcohol
Study: 27455604
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet plus two drinks per day containing 4 g inulin, 4 mg menthol, and 2 mg pyridoxine for 2 weeks
Study: 15578008
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nefazodone and CBASP
Study: 10430731
Drug: Inhaled low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled low-molecular-weight heparin (enoxaparin) 2 mg/kg
Study: 7985890
Drug: Levothyroxine (thyroid‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (thyroid‐stimulating hormone level, < 0.3 mU/L)
Study: 7985890
Drug: Potassium iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium iodide (2 mg every 2 weeks)
Study: 6778352
Drug: Assisted ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted ventilation during mask inhalation anesthetic techniques
Study: 26296850
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (49 g/day) during reduced snack consumption
Study: 25108751
Drug: Chiropractic flexion-distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic flexion-distraction manipulation (8 treatments)
Study: 25108751
Drug: Chiropractic flexion-distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic flexion-distraction manipulation (18 treatments)
Study: 19608997
Drug: Thalidomide (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100-200 mg daily for up to 2 years)
Study: 15354209
Drug: IM862 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM862 (20 mg intranasally three times daily for 8 weeks)
Study: 23359969
Drug: Suxiao Jiuxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxiao Jiuxin Pill (SJP) and Western medicine
Study: 12017410
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg/d
Study: 2171046
Drug: Peptide histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peptide histidine valine (PHV) infusion
Study: 25059694
Drug: Treatment after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment after neurologic recovery
Study: 21216083
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for three years
Study: 18812629
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg 30 min prior to ASA)
Study: 18812629
Drug: L-tryptophan (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (0.5 g 30 min prior to ASA)
Study: 18812629
Drug: Aspirin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2 x 1 g daily)
Study: 15883439
Drug: Step I
Normalized name: Bexxar Dosimetric Step Iodine I-131 Tositumomab Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step I diet supplemented with soy food (SFD; 50 mg isoflavones/d)
Study: 1720478
Drug: Isradipine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (1.25 mg or 2.5 mg twice daily)
Study: 1720478
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isradipine and captopril
Study: 7326194
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) 2 mg injection
Study: 22858517
Drug: 10-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day concomitant therapy comprising esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and metronidazole 500 mg, all bid
Study: 22858517
Drug: 10-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day standard triple therapy comprising esomeprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, all bid
Study: 14991092
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment plus CPAP
Study: 11574419
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg body wt)
Study: 9535249
Drug: PFP/PFP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFP/PFP vaccine
Study: 7912767
Drug: Daily enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily enteric-coated aspirin 300 mg
Study: 3281173
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg p.o.)
Study: 3281173
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion (25 g i.v. for 30 min)
Study: 1286524
Drug: Cabergoline 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.125 mg twice weekly
Study: 1286524
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg twice weekly
Study: 4064569
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CCK‐like peptide, caerulein, and secretin
Study: 31905205
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (PosiFlush®, group A)
Study: 31905205
Drug: Heparin (Fibrilin®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (Fibrilin®, group B)
Study: 17589949
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (saline group)
Study: 17589949
Drug: Submucosal saline‐epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal saline‐epinephrine injection (epinephrine group)